PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22999071-2 2012 We retrospectively analyzed the clinical characteristics and outcomes of patients according to gender in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. Tolvaptan 180-189 arginine vasopressin Homo sapiens 121-132 22917555-2 2012 The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) examined the effects of tolvaptan in patients with worsening HF and EF <=40%. Tolvaptan 75-84 arginine vasopressin Homo sapiens 16-27 22971027-1 2012 Tolvaptan is a member of a new class of drugs, called the vaptans, that antagonize receptors of the neurohormone arginine vasopressin. Tolvaptan 0-9 arginine vasopressin Homo sapiens 122-133 23051949-3 2012 METHODS AND RESULTS: We performed a post hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, which randomized 4133 patients hospitalized for worsening HF with an ejection fraction <=40% within 48 hours of admission to tolvaptan or placebo for a median follow-up of 9.9 months. Tolvaptan 132-141 arginine vasopressin Homo sapiens 73-84 23068288-5 2012 Whereas plasma arginine-vasopressin levels, serum aldosterone concentration, and plasma renin activity mildly increased, plasma levels of B-type natriuretic peptide and atrial natriuretic peptide significantly decreased after tolvaptan treatment. Tolvaptan 226-235 arginine vasopressin Homo sapiens 24-35 21607553-1 2012 Tolvaptan, an oral, selective arginine vasopressin (AVP) V2 receptor antagonist has been approved for the treatment of euvolemic and hypervolemic hyponatremia in the United States. Tolvaptan 0-9 arginine vasopressin Homo sapiens 52-55 22357577-3 2012 METHODS AND RESULTS: A post-hoc analysis was carried out of the placebo group of the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial, which enrolled patients hospitalized for HF with an ejection fraction (EF) <=40% and no history of primary significant liver disease or acute hepatic failure. Tolvaptan 165-174 arginine vasopressin Homo sapiens 106-117 22323742-2 2012 Tolvaptan decreases aquaporin expression in renal collecting ducts, by inhibiting antidiuretic hormone (ADH)-V2 receptors, to promote free water clearance. Tolvaptan 0-9 arginine vasopressin Homo sapiens 82-102 22027579-0 2012 Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Tolvaptan 0-9 arginine vasopressin Homo sapiens 19-30 22437213-6 2012 The oral selective V(2)-receptor antagonist tolvaptan blocks arginine vasopressin effects in the renal collecting ducts, promoting aquaresis without increasing sodium/potassium excretion. Tolvaptan 44-53 arginine vasopressin Homo sapiens 70-81 22111754-1 2012 BACKGROUND: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial showed that tolvaptan use improved heart failure (HF) signs and symptoms without serious adverse events. Tolvaptan 87-96 arginine vasopressin Homo sapiens 28-39 22111754-1 2012 BACKGROUND: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial showed that tolvaptan use improved heart failure (HF) signs and symptoms without serious adverse events. Tolvaptan 125-134 arginine vasopressin Homo sapiens 28-39 21694950-2 2011 Tolvaptan inhibits the binding of arginine vasopressin to the V(2) receptors on the collecting ducts of the kidneys resulting in aquaresis, the electrolytes sparing excretion of water. Tolvaptan 0-9 arginine vasopressin Homo sapiens 43-54 21881396-7 2011 Tolvaptan is an orally active, selective V2-receptor antagonist that blocks the effects of arginine vasopressin in the renal collecting duct to promote aquaresis without increasing sodium or potassium excretion; as a result, it increases serum sodium in a controlled manner. Tolvaptan 0-9 arginine vasopressin Homo sapiens 100-111 21641352-3 2011 This study explores the clinical effects of tolvaptan, a vasopressin-2-receptor antagonist, in addition to standard medical therapies on physician-assessed signs and symptoms in hospitalized AHFS patients. Tolvaptan 44-53 arginine vasopressin Homo sapiens 57-68 21816754-0 2011 Tolvaptan inhibits ERK-dependent cell proliferation, Cl- secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Tolvaptan 0-9 arginine vasopressin Homo sapiens 128-139 21104220-8 2010 Tolvaptan is a selective antagonist of the antidiuretic effect of vasopressin without primarily affecting blood pressure and depending on the dose leads to increased excretion of free water (aquaresis). Tolvaptan 0-9 arginine vasopressin Homo sapiens 66-77 20926941-5 2010 Conivaptan is a nonselective AVP antagonist that is available intravenously, and tolvaptan is a V2 selective AVP antagonist that is available as an oral tablet. Tolvaptan 81-90 arginine vasopressin Homo sapiens 109-112 20708094-3 2010 The purpose of this review is to update the current status of experimental and clinical studies with available vasopressin receptor antagonists (conivaptan and tolvaptan) and their potential role in the treatment of HF and hyponatremia of multiple causes. Tolvaptan 160-169 arginine vasopressin Homo sapiens 111-122 20508668-0 2010 Hyponatremia: Prolonged use of the vasopressin antagonist tolvaptan is a safe and effective treatment for hyponatremia. Tolvaptan 58-67 arginine vasopressin Homo sapiens 35-46 21180368-4 2010 Tolvaptan antagonises receptors for arginine vasopressin, a hormone that regulates blood sodium levels by stimulating renal water resabsorption. Tolvaptan 0-9 arginine vasopressin Homo sapiens 45-56 22111741-0 2010 Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia. Tolvaptan 0-9 arginine vasopressin Homo sapiens 13-24 22111741-1 2010 Tolvaptan is a new vasopressin antagonist developed for the treatment of hypervolemic or euvolemic hyponatremia. Tolvaptan 0-9 arginine vasopressin Homo sapiens 19-30 20608824-7 2010 Two nonpeptide vasopressin-receptor antagonists, conivaptan and tolvaptan, have recently been approved by American and European drug authorities for clinical use. Tolvaptan 64-73 arginine vasopressin Homo sapiens 15-26 20435194-0 2010 Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Tolvaptan 224-233 arginine vasopressin Homo sapiens 165-176 20435194-3 2010 METHODS: This was a prespecified analysis of adjudicated cause-specific all-cause mortality and cardiovascular (CV) hospitalization in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, a randomized, double-blind, placebo-controlled study in patients hospitalized with worsening HF and left ventricular ejection fraction < or =40% comparing tolvaptan, an oral vasopressin receptor antagonist to placebo, in addition to standard care. Tolvaptan 210-219 arginine vasopressin Homo sapiens 151-162 20435194-3 2010 METHODS: This was a prespecified analysis of adjudicated cause-specific all-cause mortality and cardiovascular (CV) hospitalization in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, a randomized, double-blind, placebo-controlled study in patients hospitalized with worsening HF and left ventricular ejection fraction < or =40% comparing tolvaptan, an oral vasopressin receptor antagonist to placebo, in addition to standard care. Tolvaptan 395-404 arginine vasopressin Homo sapiens 151-162 20467590-6 2010 Data from phase III studies including over 5,000 patients have demonstrated that tolvaptan is a safe and well tolerated vasopressin receptor antagonist, whose long-term use is not associated with adverse outcomes. Tolvaptan 81-90 arginine vasopressin Homo sapiens 120-131 20197265-3 2010 METHODS AND RESULTS: In the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with tolvaptan, 1528 hospitalized patients (ejection fraction < or =40%) with a physical examination, laboratories, and health status [Kansas City Cardiomyopathy Questionnaire (KCCQ)] assessments 1 week after discharge were included. Tolvaptan 99-108 arginine vasopressin Homo sapiens 40-51 19092365-7 2009 Tolvaptan, conivaptan, and lixivaptan are some of the vasopressin antagonists that have been studied in heart failure. Tolvaptan 0-9 arginine vasopressin Homo sapiens 54-65 18510477-5 2008 Tolvaptan, a vasopressin receptor antagonist, has been shown to improve diuresis and symptom relief without adversely affecting renal function, and may be a promising novel therapeutic agent in the growing population of patients with heart failure. Tolvaptan 0-9 arginine vasopressin Homo sapiens 13-24 18992654-10 2008 (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan [EVEREST]; NCT00071331). Tolvaptan 73-82 arginine vasopressin Homo sapiens 13-24 20694082-2 2008 Tolvaptan is a vasopressin V(2) receptor antagonist that blocks the effect of arginine vasopressin (AVP) in reabsorbing water from the collecting ducts of the nephrons in congestive heart failure. Tolvaptan 0-9 arginine vasopressin Homo sapiens 15-26 19018685-0 2008 EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan. Tolvaptan 86-95 arginine vasopressin Homo sapiens 27-38 19018685-7 2008 This paper provides an overview of a new compound, tolvaptan, an oral selective V(2)-vasopressin antagonist in light of the recently published Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. Tolvaptan 51-60 arginine vasopressin Homo sapiens 85-96 19018685-7 2008 This paper provides an overview of a new compound, tolvaptan, an oral selective V(2)-vasopressin antagonist in light of the recently published Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. Tolvaptan 51-60 arginine vasopressin Homo sapiens 155-166 18544725-4 2008 DESIGN, SETTING, AND PARTICIPANTS: Retrospective, post hoc analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double-blind, placebo-controlled study in patients hospitalized for heart failure and having an LVEF of 40% or less. Tolvaptan 148-157 arginine vasopressin Homo sapiens 89-100 18306096-5 2008 The AVP-receptor antagonists, including conivaptan, tolvaptan, lixivaptan, and satavaptan, represent a therapeutic advance in the treatment of dilutional hyponatremia. Tolvaptan 52-61 arginine vasopressin Homo sapiens 4-7 17703139-0 2007 Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. Tolvaptan 56-65 arginine vasopressin Homo sapiens 81-84 16794787-4 2006 The vaptans are vasopressin receptor antagonists with V1a (relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or non-selective activity (conivaptan) which may be advantageous in some disorders. Tolvaptan 79-88 arginine vasopressin Homo sapiens 16-27 17384438-0 2007 Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. Tolvaptan 31-40 arginine vasopressin Homo sapiens 50-61 19804253-5 2006 An international Phase III outcome study; Efficacy of Vasopressin antagonism in hEaRt failurE outcome Study with Tolvaptan (EVEREST), evaluating the long-term efficacy and safety of tolvaptan in patients hospitalized with worsening heart failure, is currently ongoing. Tolvaptan 113-122 arginine vasopressin Homo sapiens 54-65 17657988-3 2007 Several AVP receptor antagonists, including tolvaptan and conivaptan, have shown promise in human trials for the treatment of heart failure. Tolvaptan 44-53 arginine vasopressin Homo sapiens 8-11 15926866-3 2005 Results of early trials with tolvaptan (selective vasopressin subtype 2 receptor antagonist) and conivaptan (dual vasopressin subtypes 1a and 2 receptor antagonist) have demonstrated improvement in the fluid status, osmotic balance and haemodynamic profile in patients with heart failure presenting with signs and symptoms of decompensation. Tolvaptan 29-38 arginine vasopressin Homo sapiens 50-61 16634691-0 2006 Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Tolvaptan 0-9 arginine vasopressin Homo sapiens 23-34 15880334-0 2005 Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Tolvaptan 180-189 arginine vasopressin Homo sapiens 120-131 15880334-3 2005 Tolvaptan is an oral vasopressin (V 2 ) antagonist that decreases body weight and increases urine volume without inducing renal dysfunction or hypokalemia. Tolvaptan 0-9 arginine vasopressin Homo sapiens 21-32 15880334-4 2005 The Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial is evaluating mortality, morbidity, and patient-assessed global clinical status in patients treated with tolvaptan compared with standard care. Tolvaptan 75-84 arginine vasopressin Homo sapiens 16-27 15880334-4 2005 The Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial is evaluating mortality, morbidity, and patient-assessed global clinical status in patients treated with tolvaptan compared with standard care. Tolvaptan 206-215 arginine vasopressin Homo sapiens 16-27 15926874-3 2005 In a recent randomised study, tolvaptan, a novel vasopressin antagonist, in addition to standard therapy including diuretics, increased net fluid loss resulting in decreased body weight more effectively than standard therapy alone in patients hospitalised for heart failure. Tolvaptan 30-39 arginine vasopressin Homo sapiens 49-60 34514204-1 2021 Introduction: Tolvaptan is used to treat autosomal dominant polycystic kidney disease (ADPKD) because it inhibits binding of the antidiuretic hormone vasopressin to the vasopressin V2 receptor (V2R), which suppresses the insertion of preformed water channel aquaporin 2 (AQP2) molecules in the luminal membrane of the collecting duct cells. Tolvaptan 14-23 arginine vasopressin Homo sapiens 150-161 15461553-4 2004 In the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Congestive Heart Failure trial of patients hospitalised with HF, tolvaptan 30 mg/day increased urine volume and induced a weight loss of 3.3 kg at discharge (placebo; 1.9 kg). Tolvaptan 140-149 arginine vasopressin Homo sapiens 49-60 15113814-0 2004 Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. Tolvaptan 11-20 arginine vasopressin Homo sapiens 24-35 15113814-3 2004 In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function. Tolvaptan 53-62 arginine vasopressin Homo sapiens 30-41 15695526-4 2005 Two vasopressin antagonists, in particular, tolvaptan and conivaptan, have shown promise in animal studies and small-scale human trials. Tolvaptan 44-53 arginine vasopressin Homo sapiens 4-15 32543020-9 2020 Serum sodium, as well as copeptin levels, increased with tolvaptan compared with furosemide. Tolvaptan 57-66 arginine vasopressin Homo sapiens 25-33 32683063-0 2020 Pharmacological dilutional therapy using the vasopressin antagonist tolvaptan for young patients with cystinuria: a pilot investigation. Tolvaptan 68-77 arginine vasopressin Homo sapiens 45-56 34234441-2 2021 Tolvaptan is a selective vasopressin antagonist and has emerged as a promising therapeutic option for patients with autosomal dominant polycystic kidney disease. Tolvaptan 0-9 arginine vasopressin Homo sapiens 25-36 34719623-0 2021 Serum Copeptin and Zinc-alpha2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. Tolvaptan 75-84 arginine vasopressin Homo sapiens 6-14 34719623-11 2021 Conclusion Serum BUN, copeptin and ZAG levels predict the patient response to tolvaptan, even when measured prior to treatment. Tolvaptan 78-87 arginine vasopressin Homo sapiens 22-30 35472391-3 2022 METHODS: Using data from 4,133 patients from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, we used multivariable Cox regression models to evaluate the association between rates of in-hospital change in assessments of volume overload, including b-type natriuretic peptide (BNP), N-terminal pro b-type natriuretic peptide (NT-proBNP), as well as change in hemoconcentration, with risk of all-cause mortality and a composite outcome of cardiovascular mortality or heart failure hospitalization. Tolvaptan 120-129 arginine vasopressin Homo sapiens 61-72 31039325-5 2019 Tolvaptan, a vasopressin antagonist has been shown to slow disease progression and preserve renal function. Tolvaptan 0-9 arginine vasopressin Homo sapiens 13-24 32232055-1 2020 Tolvaptan, a vasopressin V2 receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan 0-9 arginine vasopressin Homo sapiens 13-24 32734225-0 2020 Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan. Tolvaptan 154-163 arginine vasopressin Homo sapiens 113-133 32535124-3 2020 METHODS: Using data from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan) trial, we used multivariable Cox regression models to evaluate the association between in-hospital changes in estimated glomerular filtration rate (eGFR) with death and a composite outcome of cardiovascular death and hospitalization for heart failure. Tolvaptan 109-118 arginine vasopressin Homo sapiens 50-61 32734960-0 2020 Erratum Regarding "Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan" (Kid Med. Tolvaptan 173-182 arginine vasopressin Homo sapiens 132-152 32995715-1 2020 Background: The Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) score has proven useful for risk prediction in acute decompensated heart failure (ADHF). Tolvaptan 88-97 arginine vasopressin Homo sapiens 28-39 30898339-0 2019 Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Tolvaptan 55-64 arginine vasopressin Homo sapiens 7-15 30898339-6 2019 In tolvaptan-treated subjects, copeptin increased from baseline to week 3 (6.3 pmol/L versus 21.9 pmol/L, respectively). Tolvaptan 3-12 arginine vasopressin Homo sapiens 31-39 30898339-7 2019 In tolvaptan-treated subjects with higher baseline copeptin levels, a larger treatment effect was noted with respect to kidney growth rate and eGFR decline. Tolvaptan 3-12 arginine vasopressin Homo sapiens 51-59 30898339-8 2019 Tolvaptan-treated subjects with a larger percentage increase in copeptin from baseline to week 3 had a better disease outcome, with less kidney growth and eGFR decline after three years. Tolvaptan 0-9 arginine vasopressin Homo sapiens 64-72 30637666-8 2019 Therefore, tolvaptan was initiated, which corrected his hyponatremia, and the patient was discharged.In summary, tolvaptan results in stable correction of hyponatremia in patients with terminal small-cell lung cancer complicated by the syndrome of inappropriate secretion of antidiuretic hormone. Tolvaptan 113-122 arginine vasopressin Homo sapiens 275-295 30774351-4 2019 Tolvaptan, a vasopressin antagonist, could be adopted in heart failure therapy as it reduces pre- and afterload by decreasing systolic blood pressure and blood volume. Tolvaptan 0-9 arginine vasopressin Homo sapiens 13-24 30802995-4 2019 More recently, a significant amount of research has been dedicated to the use of vasopressin antagonists, specifically tolvaptan, as adjunctive therapy to loop and thiazide diuretics. Tolvaptan 119-128 arginine vasopressin Homo sapiens 81-92 30733892-3 2019 We report a case of Bortezomib-induced SIADH, in whom the use of tolvaptan, a vasopressin receptor-2 antagonist, permitted the continuation of triple combination anti-MM therapy with lenalidomide, Bortezomib and dexamethasone (RVD) in a female with aggressive disease, without the development of hyponatremia. Tolvaptan 65-74 arginine vasopressin Homo sapiens 78-89 29801549-0 2018 Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High? Tolvaptan 0-9 arginine vasopressin Homo sapiens 57-77 30364227-6 2018 We also report our experience using tolvaptan, a vasopressin receptor antagonist, in this patient to effectively maintain eunatremia. Tolvaptan 36-45 arginine vasopressin Homo sapiens 49-60 30303493-1 2018 Tolvaptan is an orally active antagonist of vasopressin (antidiuretic hormone [ADH]) V2 receptors. Tolvaptan 0-9 arginine vasopressin Homo sapiens 44-55 29629516-0 2018 Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone. Tolvaptan 23-32 arginine vasopressin Homo sapiens 110-130 28810844-1 2017 BACKGROUND: Tolvaptan slows progression of autosomal dominant polycystic kidney disease (ADPKD) by antagonizing the vasopressin-cAMP axis. Tolvaptan 12-21 arginine vasopressin Homo sapiens 116-127 28326667-1 2017 Tolvaptan, a selective vasopressin V2 receptor antagonist, is a new generation diuretic. Tolvaptan 0-9 arginine vasopressin Homo sapiens 23-34 28905441-5 2017 On the basis of recent clinical data, the blockade of V2 vasopressin receptors using tolvaptan in patients with rapidly progressing ADPKD has been granted in several countries, and a long-term randomized trial evaluating the effect of an increase in water intake in patients with CKD is on-going. Tolvaptan 85-94 arginine vasopressin Homo sapiens 57-68 28302292-3 2017 OBJECTIVES: It was hypothesized that the addition of tolvaptan to a background diuretic improved dyspnea early in patients selected for an enhanced vasopressin antagonism response. Tolvaptan 53-62 arginine vasopressin Homo sapiens 148-159 27921039-25 2016 (3) The vasopressin 2 receptor antagonist tolvaptan was approved in Europe, Canada, Japan, and Korea to slow down progression of kidney disease in ADPKD patients. Tolvaptan 42-51 arginine vasopressin Homo sapiens 8-19 28288570-1 2017 BACKGROUND: Tolvaptan is a selective vasopressin receptor antagonist. Tolvaptan 12-21 arginine vasopressin Homo sapiens 37-48 30547521-0 2016 [Vasopressin antagonist (Tolvaptan)]. Tolvaptan 25-34 arginine vasopressin Homo sapiens 1-12 27628415-1 2016 The vasopressin type-2 antagonist tolvaptan (TLV) has clinical advantages including amelioration of congestion and normalization of hyponatremia in patients with decompensated heart failure (HF). Tolvaptan 34-43 arginine vasopressin Homo sapiens 4-15 27628415-1 2016 The vasopressin type-2 antagonist tolvaptan (TLV) has clinical advantages including amelioration of congestion and normalization of hyponatremia in patients with decompensated heart failure (HF). Tolvaptan 45-48 arginine vasopressin Homo sapiens 4-15 26610908-3 2016 Tolvaptan, an antagonist of vasopressin type 2 receptor, inhibits water reabsorption in cirrhosis. Tolvaptan 0-9 arginine vasopressin Homo sapiens 28-39 27357439-0 2016 Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin. Tolvaptan 37-46 arginine vasopressin Homo sapiens 166-177 27357439-3 2016 Tolvaptan, a newly developed vasopressin-2 receptor antagonist, elicits aquaresis and improves volume overload in heart failure patients, however, the predictors of tolvaptan effectiveness and the influence on the RAAS and renal function according to tolvaptan therapy are not established. Tolvaptan 0-9 arginine vasopressin Homo sapiens 29-40 26610908-10 2016 CONCLUSIONS: These results indicate that the vasopressin-AQP2 system plays a major role in fluid retention in cirrhosis and that the pharmacological effect of tolvaptan to inhibit water reabsorption can be monitored by measurement of the dynamics of urinary AQP2 levels. Tolvaptan 159-168 arginine vasopressin Homo sapiens 45-56 26742474-3 2016 Survival rate and longitudinal models were used to estimate temporal changes in postdischarge all-cause mortality risk in 3,993 HHF patients discharged alive in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. Tolvaptan 236-245 arginine vasopressin Homo sapiens 177-188 26784173-0 2016 Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure. Tolvaptan 97-106 arginine vasopressin Homo sapiens 66-77 26784173-2 2016 The arginine vasopressin type-2 antagonist, tolvaptan, is a new-generation diuretic; it is especially indicated in patients with decompensated heart failure refractory to conventional diuretics. Tolvaptan 44-53 arginine vasopressin Homo sapiens 13-24 26885186-0 2015 Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials. Tolvaptan 32-41 arginine vasopressin Homo sapiens 9-20 26742881-0 2016 Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure. Tolvaptan 0-9 arginine vasopressin Homo sapiens 35-46 26126090-1 2015 The vasopressin inhibitor tolvaptan is clinically effective in slowing growth of renal cysts and reduction in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD), but these effects are mitigated by the associated polyuria. Tolvaptan 26-35 arginine vasopressin Homo sapiens 4-15 26374918-7 2015 A member of this class, the oral vasopressin-2 receptor antagonist tolvaptan, provides benefits related to decongestion and symptom relief in AHF patients. Tolvaptan 67-76 arginine vasopressin Homo sapiens 33-44 26237603-1 2014 Tolvaptan is an arginine vasopressin (AVP) antagonist that acts to increase excretion of free water (aquaresis) in patients without introducing electrolyte abnormalities or worsening renal function. Tolvaptan 0-9 arginine vasopressin Homo sapiens 25-36 26405324-3 2015 The use of tolvaptan, a vasopressin antagonist, outside of clinical trials has not been well characterized. Tolvaptan 11-20 arginine vasopressin Homo sapiens 24-35 25728846-3 2015 A post hoc analysis was performed in 1,907 hospitalized patients with worsening HF and reduced EF in the placebo arm of the Efficacy of Vasopressin Antagonism in HF Outcome Study with Tolvaptan (EVEREST) trial. Tolvaptan 184-193 arginine vasopressin Homo sapiens 136-147 26714385-0 2015 The Vasopressin 2 Receptor Antagonist Tolvaptan Improves Nutrition and Inflammatory States in Peritoneal Dialysis Patients with Diabetes Mellitus. Tolvaptan 38-47 arginine vasopressin Homo sapiens 4-15 24954239-0 2014 Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Tolvaptan 101-110 arginine vasopressin Homo sapiens 56-67 25268207-7 2014 CONCLUSION: If restriction of fluid intake is not tolerated by the patients the vasopressin antagonist tolvaptan provides an alternative symptomatic treatment of paraneoplastic SIADH. Tolvaptan 103-112 arginine vasopressin Homo sapiens 80-91 24965902-1 2014 BACKGROUND: Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water excretion. Tolvaptan 12-21 arginine vasopressin Homo sapiens 37-48 24511399-5 2014 Vasopressin antagonists like tolvaptan seem promising for the treatment of euvolemic and hypervolemic hyponatremia in heart failure. Tolvaptan 29-38 arginine vasopressin Homo sapiens 0-11 24095030-3 2013 In this retrospective analysis of the placebo group of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan trial, we evaluated 1,982 patients hospitalized for worsening HF with ejection fractions <=40%. Tolvaptan 130-139 arginine vasopressin Homo sapiens 71-82 24949180-3 2014 In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function. Tolvaptan 53-62 arginine vasopressin Homo sapiens 30-41 23351825-0 2013 Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Tolvaptan 234-243 arginine vasopressin Homo sapiens 174-185 23858000-4 2013 METHODS AND RESULTS: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial was an event-driven, randomized, double-blind, placebo-controlled study of tolvaptan in 4133 patients hospitalized for worsening HF with an EF <40%. Tolvaptan 96-105 arginine vasopressin Homo sapiens 37-48 23743487-0 2013 Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Tolvaptan 142-151 arginine vasopressin Homo sapiens 105-116 23743487-3 2013 METHODS AND RESULTS: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes. Tolvaptan 96-105 arginine vasopressin Homo sapiens 37-48 23059198-3 2013 METHODS AND RESULTS: Post-hoc analysis was performed on the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) study, a randomized trial of patients hospitalized with HF (n = 4133) with median follow-up of 9.9 months. Tolvaptan 140-149 arginine vasopressin Homo sapiens 81-92 23463968-2 2013 Tolvaptan is an orally active antagonist of arginine vasopressin type 2 receptors in the collecting duct of the kidney that inhibits water reabsorption without substantially affecting the electrolyte balance. Tolvaptan 0-9 arginine vasopressin Homo sapiens 53-64 23206923-3 2013 In this post hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), 3,957 patients hospitalized for worsening HF with ejection fractions <=40% were examined. Tolvaptan 104-113 arginine vasopressin Homo sapiens 45-56 23239836-3 2013 METHODS AND RESULTS: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial investigated the effects of tolvaptan in patients with worsening heart failure and ejection fraction <=40%. Tolvaptan 96-105 arginine vasopressin Homo sapiens 37-48 23239836-10 2013 Tolvaptan therapy increased the proportion of patients with elevated AVP (P<0.001), but this had no effect on mortality (hazard ratio, 0.95; 95% confidence interval, 0.72-1.24). Tolvaptan 0-9 arginine vasopressin Homo sapiens 69-72 23239836-12 2013 Tolvaptan treatment increased AVP levels during follow-up, but this incremental increase was not associated with worsened outcomes. Tolvaptan 0-9 arginine vasopressin Homo sapiens 30-33